Sunshine Biopharma, Inc.
SBFM
$1.25
$0.032.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.75% | 61.94% | 109.82% | 193.30% | 454.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.75% | 61.94% | 109.82% | 193.30% | 454.43% |
| Cost of Revenue | 53.64% | 74.29% | 130.87% | 216.08% | 494.70% |
| Gross Profit | 27.95% | 39.69% | 73.61% | 156.09% | 391.55% |
| SG&A Expenses | 37.17% | -10.70% | -13.47% | -5.05% | 14.51% |
| Depreciation & Amortization | 49.80% | 59.38% | 93.62% | 176.58% | 492.06% |
| Other Operating Expenses | 33.59% | 32.41% | 62.92% | 153.91% | 424.82% |
| Total Operating Expenses | 40.60% | 30.54% | 45.36% | 68.89% | 121.99% |
| Operating Income | -19.82% | 43.27% | 52.22% | 53.33% | 44.55% |
| Income Before Tax | -30.60% | 84.40% | 86.25% | 86.20% | 84.49% |
| Income Tax Expenses | -159.40% | -72.03% | -116.34% | 32.83% | 69.44% |
| Earnings from Continuing Operations | -13.94% | 84.21% | 86.66% | 84.98% | 83.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.94% | 84.21% | 86.66% | 84.98% | 83.15% |
| EBIT | -19.82% | 43.27% | 52.22% | 53.33% | 44.55% |
| EBITDA | -18.86% | 44.78% | 53.59% | 54.74% | 46.11% |
| EPS Basic | 85.67% | 94.25% | 91.99% | 89.02% | 82.78% |
| Normalized Basic EPS | 82.57% | 81.88% | 73.46% | 62.60% | 24.87% |
| EPS Diluted | 85.67% | 94.25% | 91.99% | 89.02% | 82.77% |
| Normalized Diluted EPS | 82.57% | 81.88% | 73.46% | 62.60% | 24.87% |
| Average Basic Shares Outstanding | 6,763.73% | 2,759.33% | 212.61% | 224.77% | 355.36% |
| Average Diluted Shares Outstanding | 6,763.73% | 2,759.33% | 212.61% | 224.77% | 355.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |